Chewy Is Down 23% in 2026. Is This a Once-in-a-Lifetime Buying Opportunity?

Shares are down ~23% YTD while the stock still trades at a rich P/E of ~52 versus the S&P 500 ~29. Chewy reported active customers +4.9% y/y to 21.2M and sales per active customer +4.9% to $595; recurring delivery revenue rose 13.6% to $2.6B and total revenue growth was 8.3%. Despite solid customer metrics and recurring revenue growth, the high valuation leaves little margin for execution risk, and the author recommends pursuing other, more compelling buying opportunities.

Analysis

Chewy currently trades as a “growth at a premium” story — the market is pricing multi-year EPS acceleration rather than a steady, low-volatility retail cashflow stream. That creates a binary outcome: smooth execution on capital-intensive initiatives (vet clinics, Rx expansion, higher AOV conversion) sustains the multiple, while any slippage forces rapid multiple compression. Quantitatively, a 50–80% premium to the market multiple implies Chewy needs mid-20s EPS CAGR over several years to justify current levels, so small misses in retention or margins amplify downside.

The vet-clinic push is the most consequential second-order development. On success it raises customer lifetime value and proprietary pet-health data that could lock customers into higher-margin recurring services; on failure it converts a logistics/digital-native cost base into a healthcare operator with staffing, regulatory and capex risk. Logistics improvements from higher subscription density can materially lower unit shipping cost, but that lever requires sustained subscription penetration gains — a one-time promo-driven bump won’t unlock the structural margin tailwind.

Near-term catalysts are earnings prints (active customers, AOV, subscription revenue) and the cadence of clinic roll-outs; macro/capital markets are the primary exogenous risk — a higher-for-longer rate path would reprioritize cash-generative defensive retail over long-duration growth. Tail risks include aggressive competitive pricing from a deep-pocketed player (Amazon) or a regulatory/liability event from vet operations; both would compress multiples quickly. Over 3–12 months, watch incremental LTV/CAC and clinic unit economics; over 12–36 months, the key read is whether Chewy’s operating model shifts toward healthcare margins or stays a logistics-heavy retail franchise.

Key Decisions for Investors

• Short CHWY via a 3–6 month put spread sized small (e.g., buy 1 ATM put / sell 1 lower strike put to fund) with target return of 2–3x premium if shares fall 25–40% after a soft print. R/R: limited downside to premium paid, asymmetric upside if multiple compresses on missed retention or clinic execution.
• Pair trade: short CHWY (size X) / use proceeds to go long NVDA (size ~0.5X) for 3–9 months — rationale: rotate out of high-duration consumer growth into secular AI exposure. Expect NVDA to outperform if risk-on re-rates growth; risk is NVDA already priced for perfection, cap gains should be taken at 20–30%.
• If constructive on long-term upside but wary of execution risk, buy CHWY 12–18 month call spreads (debit spread) funded by selling nearer-term calls (calendar-like) to express a conditional multi-quarter operational recovery. Target >40% upside over 12–18 months to justify position; capped loss = net premium.
• Small speculative long INTC 6–12 month call spread as a hedge to the pair above — cheap exposure to semi-dollar upcycle that benefits from any risk-on reallocation away from cyclical retail. Keep allocation <5% of the CHWY short notional due to earnings/cycle sensitivity.